astrazeneca plc - AZNCF

AZNCF

Close Chg Chg %
140.10 7.37 5.26%

Closed Market

147.47

+7.37 (5.26%)

Volume: 2.57K

Last Updated:

Mar 28, 2025, 2:58 PM EDT

Company Overview: astrazeneca plc - AZNCF

AZNCF Key Data

Open

$146.75

Day Range

145.37 - 148.92

52 Week Range

120.64 - 175.00

Market Cap

$217.24B

Shares Outstanding

1.55B

Public Float

1.47B

Beta

0.41

Rev. Per Employee

N/A

P/E Ratio

31.59

EPS

$4.54

Yield

218.42%

Dividend

$2.12

EX-DIVIDEND DATE

Feb 20, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

1.38K

 

AZNCF Performance

1 Week
 
-3.88%
 
1 Month
 
-1.99%
 
3 Months
 
11.72%
 
1 Year
 
7.67%
 
5 Years
 
73.29%
 

AZNCF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About astrazeneca plc - AZNCF

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

AZNCF At a Glance

AstraZeneca PLC
Cambridge Biomedical Campus
Cambridge, Cambridgeshire CB2 0AA
Phone 44-20-3749-5000 Revenue 54.07B
Industry Pharmaceuticals: Major Net Income 7.04B
Sector Health Technology 2024 Sales Growth 18.035%
Fiscal Year-end 12 / 2025 Employees 94,300
View SEC Filings

AZNCF Valuation

P/E Current 31.595
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 28.885
Price to Sales Ratio 3.79
Price to Book Ratio 4.984
Price to Cash Flow Ratio 16.791
Enterprise Value to EBITDA 12.862
Enterprise Value to Sales 4.247
Total Debt to Enterprise Value 0.132

AZNCF Efficiency

Revenue/Employee 573,414.634
Income Per Employee 74,602.333
Receivables Turnover 4.13
Total Asset Turnover 0.527

AZNCF Liquidity

Current Ratio 0.927
Quick Ratio 0.737
Cash Ratio 0.203

AZNCF Profitability

Gross Margin 74.982
Operating Margin 23.651
Pretax Margin 16.124
Net Margin 13.01
Return on Assets 6.858
Return on Equity 17.603
Return on Total Capital 9.897
Return on Invested Capital 10.759

AZNCF Capital Structure

Total Debt to Total Equity 74.278
Total Debt to Total Capital 42.62
Total Debt to Total Assets 29.12
Long-Term Debt to Equity 67.717
Long-Term Debt to Total Capital 38.856
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Astrazeneca Plc - AZNCF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
37.83B 44.35B 45.81B 54.07B
Sales Growth
+37.11% +17.23% +3.29% +18.03%
Cost of Goods Sold (COGS) incl D&A
14.79B 16.25B 11.93B 13.53B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.10B 5.25B 4.93B 5.07B
Depreciation
959.00M 1.10B 1.01B 1.14B
Amortization of Intangibles
3.14B 4.16B 3.93B 3.92B
COGS Growth
+106.25% +9.85% -26.56% +13.36%
Gross Income
23.04B 28.10B 33.88B 40.55B
Gross Income Growth
+12.82% +21.97% +20.55% +19.68%
Gross Profit Margin
+60.90% +63.36% +73.95% +74.98%
2021 2022 2023 2024 5-year trend
SG&A Expense
20.13B 23.04B 24.47B 27.76B
Research & Development
8.55B 9.64B 10.35B 12.22B
Other SG&A
11.58B 13.40B 14.12B 15.54B
SGA Growth
+27.83% +14.47% +6.18% +13.45%
Other Operating Expense
- - - 47.00M
-
Unusual Expense
3.83B 2.13B 2.03B 3.14B
EBIT after Unusual Expense
(963.00M) 2.93B 7.38B 9.64B
Non Operating Income/Expense
1.54B 460.00M 665.00M 465.00M
Non-Operating Interest Income
12.00M 78.00M 291.00M 339.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
774.00M 889.00M 1.13B 1.39B
Interest Expense Growth
+5.16% +14.86% +27.33% +22.88%
Gross Interest Expense
774.00M 889.00M 1.13B 1.39B
Interest Capitalized
- - - -
-
Pretax Income
(201.00M) 2.51B 6.91B 8.72B
Pretax Income Growth
-105.10% +1,346.77% +175.78% +26.16%
Pretax Margin
-0.53% +5.65% +15.09% +16.12%
Income Tax
(380.00M) (792.00M) 938.00M 1.65B
Income Tax - Current - Domestic
1.20B 1.64B 2.45B 2.45B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(1.58B) (2.43B) (1.51B) (795.00M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
115.00M 3.29B 5.96B 7.04B
Minority Interest Expense
3.00M 5.00M 6.00M 6.00M
Net Income
112.00M 3.29B 5.96B 7.04B
Net Income Growth
-96.50% +2,835.71% +81.11% +18.14%
Net Margin Growth
+0.30% +7.41% +13.00% +13.01%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
112.00M 3.29B 5.96B 7.04B
Preferred Dividends
- - - -
-
Net Income Available to Common
112.00M 3.29B 5.96B 7.04B
EPS (Basic)
0.079 2.124 3.8444 4.5387
EPS (Basic) Growth
-96.76% +2,588.61% +81.00% +18.06%
Basic Shares Outstanding
1.42B 1.55B 1.55B 1.55B
EPS (Diluted)
0.0785 2.1077 3.8124 4.501
EPS (Diluted) Growth
-96.77% +2,584.97% +80.88% +18.06%
Diluted Shares Outstanding
1.43B 1.56B 1.56B 1.56B
EBITDA
6.97B 10.31B 14.35B 17.85B
EBITDA Growth
-8.11% +48.06% +39.08% +24.46%
EBITDA Margin
+18.41% +23.26% +31.31% +33.02%

Astrazeneca Plc in the News